Eloxx Pharmaceuticals Inc Dossier - Source-backed chat

Eloxx Pharmaceuticals Inc

ELOXOTC Pink Market

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.00

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $15.71Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $54M

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations. Following a successful $66.0 million public offering and uplisting to the Nasdaq Capital Market in June 2026, the company has significantly bolstered its balance sheet, resolving its previous going concern doubts. This capital injection fully funds the upcoming Phase 2b EXACT trial of its lead asset, exaluren, in Nonsense Mutation Alport Syndrome (NMAS), which is scheduled to initiate in Q3 2026. With a strong scientific foundation, a validated mechanism of action, and a high-value out-licensing partnership with Almirall for ZKN-013, Eloxx represents a high-upside opportunity in the rare genetic kidney disease space.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$43.00

Mean target$43.00

High · most bullish analyst$43.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$43.0020%

The Phase 2b EXACT trial faces severe patient enrollment delays or fails to show a meaningful clinical benefit over placebo in the 16-week readout. Cash burn accelerates faster than anticipated, forcing highly dilutive equity raises at depressed valuations, while partner Almirall experiences setbacks with ZKN-013.

Base CaseCentral scenario

$43.0050%

Matches the consensus mean

Eloxx successfully initiates and completes the Phase 2b EXACT trial of exaluren in NMAS, with topline 16-week data by mid-2027 showing consistent biomarker improvements (reduction in podocyte foot process effacement and improved glomerular basement membrane width) similar to Phase 2a. The company initiates its Phase 2 trial in nmADPKD in 2027, maintaining steady progress and securing additional strategic interest.

Bull CaseUpside scenario

$43.0030%

The Phase 2b EXACT trial of exaluren in NMAS demonstrates robust, statistically significant improvements in kidney architecture and filtration slit density, leading to rapid FDA approval pathways. Simultaneously, Almirall successfully advances ZKN-013 in rare skin diseases, triggering substantial milestone payments. The company's platform is validated, and it expands its pipeline into other nonsense mutation-driven indications.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Secured $66.0 million in gross proceeds from a June 2026 public offering, resolving immediate going concern risks and fully funding key clinical trials.
Uplisted to the Nasdaq Capital Market, enhancing stock liquidity and institutional investor access.
Lead asset exaluren has a gene-agnostic mechanism targeting the root cause of rare kidney diseases (NMAS and nmADPKD) caused by nonsense mutations.
Strong validation from a Phase 2a proof-of-concept trial showing structural kidney improvements in all treated patients.
Valuable partnership with Almirall for ZKN-013, providing up to $470 million in potential milestone payments plus royalties.

Key Investment Risks

Clinical execution risk associated with the upcoming Phase 2b EXACT trial and planned Phase 2 nmADPKD trial.
High dependence on a single primary therapeutic candidate (exaluren) for near-term value creation.
Potential for future dilutive capital raises if clinical timelines extend or development costs exceed expectations.

Thesis Invalidation Triggers

Failure of exaluren to show statistical significance or clinical efficacy in the Phase 2b EXACT trial 16-week placebo-controlled readout.
Severe safety or tolerability issues emerging during clinical trials of exaluren.
Termination or significant delay of the ZKN-013 development program by partner Almirall.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.